Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
US appeals court revives Regeneron's antitrust lawsuit against Novartis
10:16am, Monday, 18'th Mar 2024
A U.S. appeals court on Monday revived an antitrust lawsuit by Regeneron Pharmaceuticals against Novartis related to prescription treatments to address a condition that can lead to eye disorders inclu
Here is What to Know Beyond Why Novartis AG (NVS) is a Trending Stock
10:00am, Thursday, 14'th Mar 2024
Novartis (NVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novartis (NVS) Stock Dips While Market Gains: Key Facts
07:06pm, Tuesday, 12'th Mar 2024
In the most recent trading session, Novartis (NVS) closed at $99.77, indicating a -1.58% shift from the previous trading day.
Novartis (NVS) Advances While Market Declines: Some Information for Investors
07:21pm, Monday, 11'th Mar 2024
Novartis (NVS) closed the most recent trading day at $101.37, moving +0.66% from the previous trading session.
3 Stocks Primed for Exponential Returns by 2034
03:10pm, Friday, 01'st Mar 2024
With the S&P500 practically at all-time highs, it's no understatement to say that the stock market is booming. From AI to consumer goods, many industries are reporting favorable earnings growth at the
Is Trending Stock Novartis AG (NVS) a Buy Now?
10:01am, Friday, 01'st Mar 2024
Novartis (NVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
20 GARP Blue-Chip Bargains To Buy Now
07:00am, Friday, 01'st Mar 2024
Last week saw a rally in Nvidia stock, causing nervousness among value and income investors. There were opportunities to buy quality companies at good or even great valuations even during the tech bub
27 Upcoming Dividend Increases Including A Dividend King
12:15pm, Thursday, 29'th Feb 2024
A new list of 27 new dividend increases, including King Kimberly-Clark and three other champions.
Here's Why Novartis (NVS) Fell More Than Broader Market
07:01pm, Wednesday, 28'th Feb 2024
Novartis (NVS) reachead $102.22 at the closing of the latest trading day, reflecting a -0.9% change compared to its last close.
UK's MHRA revokes authorisation for Novartis' sickle cell drug
06:20am, Wednesday, 21'st Feb 2024
Britain's health regulator said on Wednesday it had revoked a conditional marketing authorisation for Novartis' sickle cell disease drug, Adakveo.
Novartis (NVS) to Buy MorphoSys & Add Late-Stage Oncology Drug
12:21pm, Tuesday, 06'th Feb 2024
Novartis (NVS) announces an agreement to acquire Germany-based MorphoSys AG and add the latter's late-stage candidate pelabresib to its pipeline.
Novartis to acquire German Biotech MorphoSys for $2.9B, Expanding Cancer Drug Pipeline
10:45am, Tuesday, 06'th Feb 2024
Novartis (NVS) has struck a deal to buy German biotech firm MorphoSys (MOR), a developer of cancer treatments, for 2.7 billion euros ($2.9 billion), as the Swiss drugmaker expands its roster of cancer
Novartis to buy cancer drug maker MorphoSys for €2.7 billion
08:51am, Tuesday, 06'th Feb 2024
Novartis AG has announced the acquisition of Germany-based cancer drug maker MorphoSys AG through a €2.7 billion deal. Unveiling the takeover on Monday, Novartis said the move would expand its oncol
Novartis to bolster its oncology portfolio with acquisition of MorphoSys
11:05pm, Monday, 05'th Feb 2024
Novartis AG on Monday announced it has agreed to buy German biopharmaceutical company MorphoSys AG for 2.7 billion euros ($2.9 billion).
Novartis acquiring cancer drug developer Morphosys for €2.7 billion
05:16pm, Monday, 05'th Feb 2024
CNBC's Steve Kovach joins 'Closing Bell Overtime' with breaking news out of the pharmaceutical space.
